Discovery Park’s Infrastructure Facilitates New Companies

**INITIATIVE**

Medtric has received mentoring and financial support via the Purdue Realization and Entrepreneurship Ph.D. and Postdoctoral (PREPP) Fellowship Program, which is supported by Discovery Park’s Burton D. Morgan Center for Entrepreneurship through a Kauffman Foundation grant, and via the Purdue Research Park and Purdue’s business plan competitions. Jianming Li, a research professor in the Department of Basic Medical Sciences, and Sean Connell, a PhD alumni in biomedical engineering, are the co-founders of Medtric and co-inventors of the technology. Both have been participants in PREPP as well as other Discovery Park programs such as the Discovery Undergraduate Research Internship Program (mentoring undergraduates for a project), and the Entrepreneurial Leadership Academy.

**www.medtricbiotech.com**

Medtric, LLC, was founded in 2010 with a vision to deliver clinically relevant and economically sensible solutions for the prevention and treatment of infected wounds. The company’s core technologies are novel broad spectrum antimicrobial nanoemulsions. These platforms were developed at Purdue and offer a promising alternative to traditional antibiotic or metal ion therapies. Additional applicable markets include consumer, agricultural and industrial sanitation. Medtric’s initial target market is in the wound care sector, where the emulsions serve as potential therapeutics for antiseptics and traumatic wound care.

The expertise and funding support from Discovery Park and the entire Purdue entrepreneurial community has helped Medtric obtain national accolades such as first place in the Licensing Executives Society, Burton D. Morgan, Wake Forest University and Purdue Life Sciences Business Plan competitions. Additionally, the team finished second in the Rice Business plan competition and has had top-five placements in cities such as Cincinnati, Austin, Louisville, San Diego and New York.

**IMPACT**

Medtric is building on the success of these endeavors by reinvesting the capital into intellectual property and R&D. Ongoing pre-clinical and animal trials point to positive results. Medtric aims to enter into the human over-the-counter market later this year with an antiseptic and hand sanitizer versions of the technology. The company is also pursuing global strategic partners, especially in Asia. The nanoemulsion wound care technology was supported by an NSF SBIR Phase 1 and 1B grants. The founding researchers are seeking additional funding from sources such as the National Institutes of Health and the U.S. Department of Defense, as well as private equity investments.